VivoSeq
Oncology

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

10

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 is an early-stage landscape with 10 programs across 7 companies. The most active players are Regeneron, Teva, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 2Teva logo

Teva

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3A

Avyxa

2 programs

Phase 3Roche logo

Roche

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

10programs
Small molecule550%
Monoclonal antibody550%

Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

3

clinical trials

Active, not recruiting3 · 100%

Clinical Trials

Trial Activity

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 3·NCT05721755·290 enrolled
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT05063552·430 enrolled
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Active, not recruiting·—·Phase 2·NCT04862650·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)